{"title":"主要组织相容性复合体II类缺乏的细胞和基因治疗。","authors":"Franck Matheux, Jean Villard","doi":"10.1152/nips.01462.2003","DOIUrl":null,"url":null,"abstract":"<p><p>Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.</p>","PeriodicalId":82140,"journal":{"name":"News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society","volume":"19 ","pages":"154-8"},"PeriodicalIF":0.0000,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1152/nips.01462.2003","citationCount":"18","resultStr":"{\"title\":\"Cellular and gene therapy for major histocompatibility complex class II deficiency.\",\"authors\":\"Franck Matheux, Jean Villard\",\"doi\":\"10.1152/nips.01462.2003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.</p>\",\"PeriodicalId\":82140,\"journal\":{\"name\":\"News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society\",\"volume\":\"19 \",\"pages\":\"154-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1152/nips.01462.2003\",\"citationCount\":\"18\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1152/nips.01462.2003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1152/nips.01462.2003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cellular and gene therapy for major histocompatibility complex class II deficiency.
Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
